Immunoengineering Industry Symposium
"Tuning the Immune Response with Advanced Therapeutics"
A symposium showcasing immunoengineering industry leaders who will present overviews of their companies and products and share valuable perspectives from their own professional journeys. This event is open to both trainees and faculty engaged in immunoengineering research at Georgia Tech and Emory University.
AGENDA
8:30 a.m. Check-in ~ Continental Breakfast
8:55 a.m. Opening remarks – Julia Babensee and Susan Thomas, Symposium Co-Chairs
Session I
Session Chair – Susan Thomas
9:00 a.m. Keynote Presentation - “Translating Prime Editing into Genetic Medicines” - Ann Lee, Chief Technical Officer, Prime Medicine
10:00 a.m. Break
10:30 a.m. “ImmuneEngineering Autologous Adaptive Cell Therapy (AACT) Manufactured at the Point of Care” - John Powderly, MD, Founder and President, Carolina BioOncology Institute, BioCytics Human Applications Lab
11:15 a.m. “An Adventure in Developing Lymphatic Therapies for the Treatment of Rheumatoid Arthritis and Cutaneous T Cell Lymphoma” - Russell “Rusty” Ross, Chief Technical Officer, Sofusa™ Business Unit, Sorrento Therapeutics
12:00 p.m. Poster Session / Lunch – Nerem Atrium
Session II
Session Chair – Julia Babensee
1:00 p.m. "A Scientist’s View on Navigating Regulatory Development of a Personalized Cancer Vaccine Immunotherapy Through Early Clinical Trials" - Kristen Jacobsen, Senior Scientist, Metaclipse Therapeutics Corporation
1:45 p.m. "Developing γδT Cells as an Allogeneic Cell Therapy Platform” - Brian Petrich, Director of Oncology, Expression Therapeutics
2:30 p.m. Break
2:45 p.m. “Nonviral Manufacturing of Genome-edited, Immune Cell Therapies” - Krishanu Saha, Professor of Biomedical Engineering & Retina Research Foundation Kathryn and Latimer Murfee Chair, University of Wisconsin-Madison
3:30 p.m. Final remarks ~ Adjourn
Thank you to Georgia Tech's Office of the Executive Vice President for Research for their support of this meeting through the NIH T32 Training Grant "Research Program in Immunoengineering," and for the support from the Parker H. Petit Institute for Bioengineering and Bioscience.
